VERTEX PHARMACEUTICALS INC / MA

VRTX · CIK 0000875320

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$12.00B8.9%

FY2025

Net income (FY)

$3.95B838.1%

FY2025

Free cash flow (FY)

$3.19B504.1%

FY2025

Diluted EPS (FY)

$15.32836.5%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 68.4× since FY2008 · net margin -630.3% → 32.9%

MarginsNet marginFCF margin

FY2025: net 32.9% · free cash flow 26.6% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $3.63B operating cash − $437.6M capex = $3.19B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -59% (FY2009) → 21% (FY2025) · on assets 15.4%

Balance sheetLiabilitiesEquity

FY2025: $25.64B assets · $6.98B liabilities · $18.67B equity

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	2,987	3,076	2,965	2,770	2,772	2,646	2,691	2,484	2,493	2,375	2,334	2,196
Net income	1,031	1,083	1,033	646	1,045	(3,594)	1,100	1,035	916	700	931	811
Diluted EPS	4.02	4.20	3.99	2.49	4.01	(13.92)	4.21	3.97	3.52	2.69	3.59	3.13
Diluted shares	256	258	259	260	261	258	261	261	260	260	260	259
Operating cash flow	1,428	—	—	819	—	—	1,307	—	—	900	—	—
Capital expenditures	133	—	—	41	—	—	68	—	—	42	—	—
Free cash flow	1,295	—	—	778	—	—	1,238	—	—	858	—	—
Cash & equivalents	5,493	4,940	4,972	4,675	5,239	4,580	9,158	11,110	10,151	9,290	9,172	8,702
Total assets	26,484	24,862	24,037	22,881	22,240	20,132	23,917	21,726	20,349	18,974	16,706	15,582
Total liabilities	7,123	7,544	6,861	6,384	6,609	5,357	5,371	5,213	4,879	4,542	3,677	3,649
Shareholders' equity	19,362	17,319	17,175	16,496	15,631	14,775	18,547	16,513	15,470	14,432	13,030	11,934

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.